Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -23.93% is 33% above its 3-year average of -35.57%, near the high end of its 3-year range (-57.96%–-22.58%).
4.86% below its 12-month average of -22.82%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.51%.
RETURN ON ASSETS (ROA)
-23.93%
RETURN ON ASSETS (ROA) AVG TTM
-22.82%
RETURN ON ASSETS (ROA) AVG 3Y
-35.57%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.86%
CURRENT VS 3Y AVG
+32.72%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.15%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
+17.91%
vs the sector median at left
MBX Biosciences, Inc. Common Stock
Market Cap
$2.67B
Return on Assets (ROA)
-23.93%
TTM Avg
-22.82%
3Y Avg
-35.57%
5Y Avg
N/A
Market Cap
$2.69B
Return on Assets (ROA)
-20.31%
TTM Avg
-7.83%
3Y Avg
-2.64%
5Y Avg
-2.82%
Market Cap
$2.69B
Return on Assets (ROA)
13.04%
TTM Avg
11.11%
3Y Avg
0.70%
5Y Avg
-8.32%
Market Cap
$2.71B
Return on Assets (ROA)
-0.24%
TTM Avg
-15.97%
3Y Avg
-8.17%
5Y Avg
-3.53%
Market Cap
$2.58B
Return on Assets (ROA)
-36.84%
TTM Avg
-27.21%
3Y Avg
-27.53%
5Y Avg
-29.44%
Market Cap
$2.58B
Return on Assets (ROA)
-6.16%
TTM Avg
-19.77%
3Y Avg
-17.54%
5Y Avg
-23.06%
Market Cap
$2.78B
Return on Assets (ROA)
1.56%
TTM Avg
-4.54%
3Y Avg
-5.50%
5Y Avg
-3.43%
Market Cap
$2.79B
Return on Assets (ROA)
10.36%
TTM Avg
11.11%
3Y Avg
1.40%
5Y Avg
-7.68%
Market Cap
$2.82B
Return on Assets (ROA)
-52.25%
TTM Avg
-41.76%
3Y Avg
-70.33%
5Y Avg
-55.50%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MBX Biosciences, Inc. Common Stock (MBX) | $2.67B | -23.93% | -22.82% | -35.57% | N/A |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | -20.31% | -7.83% | -2.64% | -2.82% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 13.04% | 11.11% | 0.70% | -8.32% |
| Neogen Corporation (NEOG)vs › | $2.71B | -0.24% | -15.97% | -8.17% | -3.53% |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.58B | -36.84% | -27.21% | -27.53% | -29.44% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.58B | -6.16% | -19.77% | -17.54% | -23.06% |
| AtriCure, Inc. (ATRC)vs › | $2.78B | 1.56% | -4.54% | -5.50% | -3.43% |
| TransMedics Group, Inc. (TMDX)vs › | $2.79B | 10.36% | 11.11% | 1.40% | -7.68% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.82B | -52.25% | -41.76% | -70.33% | -55.50% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.43B | -2.55% | -11.61% | -25.65% | -35.91% |
ROA
-23.9%
ROE
-25.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -22.58% |
| 2024-12-31 | -23.06% |
| 2023-12-31 | -38.68% |
| 2022-12-31 | -57.96% |
